Brentuximab vedotin plus R-CHP for EBV+ lymphoma
Part of Digestive system clinical trials.
This trial tests a new combination of targeted antibody-drug (brentuximab vedotin) plus standard chemotherapy (R-CHP) for people with a specific type of aggressive lymphoma that has a virus (EBV) in the tumor cells. The goal is to see if this combination works better than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma called EBV-positive DLBCL, not otherwise specified, as diagnosed by a biopsy.
- You have at least one tumor that can be measured on a PET/CT scan (largest part at least half an inch in lymph nodes or one-third of an inch in other organs).
- You are between 18 and 70 years old and your overall health is good enough to get up and do daily tasks (ECOG score 0-2).
- Your blood counts, liver, kidney, and heart function are within safe limits based on recent tests.
- You agree to use effective birth control during treatment and for 3 months afterward if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug brentuximab vedotin can help prevent lymphoma from coming back after a stem cell transplant. It is for people with a specific type of skin lymphoma called mycosis fungoides.
This trial tests the drug brentuximab vedotin for children and young adults (ages 2 to under 35) who have just been diagnosed with classical Hodgkin lymphoma. The treatment is guided by PET/CT scans to see how well it works.
This trial tests a combination of two targeted drugs, chidamide and brentuximab vedotin, for people with a type of T-cell lymphoma that has the CD30 protein. It is for patients who are older or not healthy enough for standard chemotherapy, and whose cancer has come back or not responded to previous treatment.
This study looks at how well a combination drug treatment (brentuximab vedotin plus chemotherapy) works for patients with rare T-cell lymphomas in real-world clinical practice in Spain. It focuses on patients receiving this as their first treatment.
This trial tests a drug called brentuximab vedotin (BV) in people whose Hodgkin lymphoma has come back or not responded to treatment. It aims to see if BV can help shrink or control the cancer.
This trial tests a combination of two drugs (brentuximab vedotin, AVD chemotherapy) for people with newly diagnosed, bulky Hodgkin lymphoma that hasn't spread far. It aims to see if this treatment works well for larger tumors.
Hear when a new Brentuximab Vedotin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.